Inspira Technologies OXY B.H.N. Ltd.(IINN)Earnings, Financials & Key Ratios

IINN•NASDAQ

$1.61

Price updated Jul 6, 2026

SectorHealthcare IndustryMedical Devices Sub-IndustryRespiratory and sleep therapy devices

AboutInspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.Show more

Revenue$289K
EBITDA-$13M-115198.8%
Net Income-$13M-119505.5%
EPS (Diluted)-0.45-74900.0%
Gross Margin-94.12%
EBITDA Margin-4555.36%
Operating Margin-4710.73%
Net Margin-4574.39%
ROE-397.89%-181007.5%

IINN Price & Volume

Inspira Technologies OXY B.H.N. Ltd. (IINN) stock price & volume — 10-year historical chart

Loading chart...

Persistent R&D Burn Challenges Commercialization Growth Path

Investment Thesis • Updated 2025Q2

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Capital dilution and regulatory failure

Key Thesis Takeaways

Inspira Technologies remains in a high-risk, pre-commercial phase, characterized by a structural reliance on capital markets to fund its $1.8 million quarterly R&D expenditure.
While the company is attempting to transition toward commercializing its Augmented Respiration Technology, the lack of meaningful revenue generation—totaling only $144.5K in 2025Q2—leaves the firm vulnerable to significant dilution.
Investors should monitor the company's ability to secure regulatory milestones, as the current $2.1 million cash position provides a limited runway against ongoing operating losses.

Verdict Logic

the company's precarious liquidity position, highlighted by a $2.1 million cash balance against quarterly operating losses of $3.6 million, suggests an imminent risk of dilutive capital raises that could significantly impair shareholder value.

IINN Growth Metrics

Inspira Technologies OXY B.H.N. Ltd. (IINN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-15.75%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM28.74%

Return on Capital

10 Years-2988.14%

5 Years-104.84%

3 Years-164.81%

Last Year-377.28%

Latest IINN News

Recent stock market news and headlines for Inspira Technologies OXY B.H.N. Ltd. (IINN)

GlobeNewsWire·5 days ago

QTREX Engineers Conductivity Itself to Address Quantum Computing's Cryogenic Heat-Load Barrier

The Company Filed a U.S. Provisional Patent Application Covering a Potentially Dominant Approach to the Critical Cryogenic Signal Pathway, Designed to Overcome Limitations of Traditional Manufacturing The Company Filed a U.S. Provisional Patent Application Covering a Potentially Dominant Approach to the Critical Cryogenic Signal Pathway, Designed to Overcome Limitations of Traditional Manufacturing

Peers Comparison

Key metrics vs top competitors for Inspira Technologies OXY B.H.N. Ltd. (IINN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
IINNInspira Technologies OXY B.H.N. Ltd.Current	$1.61	$43.12M	-3.58	—	-4574.39%	-397.89%	—
AVAVAeroVironment, Inc.	$176.84	$8.95B	-32.75	140.89%	-13.41%	-6.05%	—
LUNGPulmonx Corporation	$1.48	$62.51M	-1.11	8.01%	-60.09%	-92.94%	—
SPROSpero Therapeutics, Inc.	$2.19	$126.8M	14.60	24.27%	27.82%	35.58%	—
GMEDGlobus Medical, Inc.	$80.50	$10.86B	20.54	16.65%	18.92%	13.04%	—
INVAInnoviva, Inc.	$21.82	$1.61B	6.61	18.52%	118.91%	47.59%	—

Compare IINN vs Peers

Inspira Technologies OXY B.H.N. Ltd. (IINN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AVAV

Most directly comparable listed peer for IINN.

Scale Benchmark

vs LIN

Larger-name benchmark to compare IINN against a more recognizable public peer.

Peer Set

Compare Top 5

vs AVAV, LUNG, SPRO, GMED

Get notified when IINN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

IINN Frequently Asked Questions

Inspira Technologies OXY B.H.N. Ltd. (IINN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Inspira Technologies OXY B.H.N. Ltd.'s revenue?

Inspira Technologies OXY B.H.N. Ltd. (IINN) reported $0.3M in revenue for fiscal year 2025.

Is IINN profitable?

Inspira Technologies OXY B.H.N. Ltd. (IINN) reported a net loss of $12.6M for fiscal year 2025.

Dividend & Returns

What is IINN's return on equity?

Inspira Technologies OXY B.H.N. Ltd. (IINN) has a return on equity (ROE) of -397.9%. Negative ROE indicates the company is unprofitable.

What is Inspira Technologies OXY B.H.N. Ltd.'s free cash flow?

Inspira Technologies OXY B.H.N. Ltd. (IINN) had negative free cash flow of $10.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in IINN back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

IINNInspira Technologies OXY B.H.N. Ltd.Current

$1.61

$43.12M

-3.58

—

-4574.39%

-397.89%

—

AVAVAeroVironment, Inc.

$176.84

$8.95B

-32.75

140.89%

-13.41%

-6.05%

—

LUNGPulmonx Corporation

$1.48

$62.51M

-1.11

8.01%

-60.09%

-92.94%

—

SPROSpero Therapeutics, Inc.

$2.19

$126.8M

14.60

24.27%

27.82%

35.58%

—

GMEDGlobus Medical, Inc.

$80.50

$10.86B

20.54

16.65%

18.92%

13.04%

—

INVAInnoviva, Inc.

$21.82

$1.61B

6.61

18.52%

118.91%

47.59%

—